Progressive Langerhans' cell histiocytosis in a puppy

A 8-month-old, female miniature Dachshund dog was presented for the complaint of pruritic, generalized, multiple nodules and plaques. Two months previously, a nodule on the left pinna was excised and diagnosed as a cutaneous histiocytoma. One month post-excision, a nodule reappeared at the same site and, shortly thereafter, additional nodules developed. Histopathological examination revealed a diffuse proliferation of histiocytic cells, which reacted strongly to antibodies for vimentin and lysozyme. Immunophenotypic analysis showed that most of the cells expressed CD1a, CD1c, CD11c, CD18, CD45 and MHC class II markers. Electron microscopic examination revealed cytoplasmic filopodia and paracrystalline structures. These findings indicated that the cells originated from Langerhans' cell. The disease progressed despite glucocorticoid therapy and griseofulvin was administered as an immunomodulating drug. All lesions resolved completely after 7 weeks of griseofulvin treatment. The dog, however, died three months later after discontinuation of griseofulvin therapy and a necropsy was not performed. It is considered that the present canine dermatosis corresponds with a severe form of Langerhans' cell histiocytosis in humans rather than canine cutaneous histiocytoma.     

Treatment of cutaneous T-cell lymphoma with dacarbazine in a dog

Abstract Epitheliotropic cutaneous T-cell lymphoma in a Lhasa Apso dog treated with dacarbazine is reported. Clinical disease consisted of a 4 × 4-cm ulcerated mass over the mandibular symphysis and bilateral lymphadenopathy of the submandibular lymph nodes. Skin biopsy sections were díagnostic for epitheliotropic cutaneous T-cell lymphoma, and immunohistochemistry staining for the CD3 antigen was positive. Tissue samples were submitted for chemosensitivity testing and dacarbazine was shown to be 60% effective. Treatment with dacarbazine resulted in total clinical remission. The dog remains disease free 1 year after treatment. Résumé— Les auteurs décrivent un cas de lymphome cutané T épithéliotrope chez un Lhassa Apso traitéà la dacarbazine. Le tableau clinique était caractérisé par la présence d'une masse ulcérée de 4 × 4 cm sur la symphyse mandibulaire et par une adénopathie bilatérale des ganglions sous mandibulaires. Les biopsies posèrent le díagnostic de lymphome cutané T et l'immunomarquage fut positif pour l'antigène CD3. Des prélèvements tissulaires fürent soumis à des tests de chimiosensibilité et la dacarbazine se révéla efficace à 60%. Le traitement à la dacarbazine entraina une rémission clinique totale. Le chien ne présente pas de récidive un an après le traitement. [Lemarié, S. L., Eddlestone, S. M. Treatment of cutaneous T-cell lymphoma with dacarbazine in a dog. (Traitement d'un lymphome cutané T à la dacarbazine chez un chien.) Veterinary Dermatology 1997; 8 : 41–46.] Resumen Se describe el tratamiento con dacarbazina de un linfoma cutáneo epiteliotrópico de células T en un Lasha Apso. La presentación clinica consistia en una masa ulcerada de 4 × 4 cm por encima de la sinfisis mandibular y linfadenopatia bilateral de los ganglios linfáticos submandibulares. El estudio histológico cutáneo permitió un díagnóstico de linfoma cutáneo epiteliotrópico de celulas T, con positividad inmunohistoquimica al antigeno CD3. Se remitieron muestras tisulares para pruebas de quimiosensibilidad, en las que la dacarbazina mostró una efectividad del 60%. El tratamiento con dacarbazina llevó a una remisión clinica total. El perro sigue sano un año después del tratamiento. [Lemarié, S. L., Eddlestone, S. M. Treatment of cutaneous T-cell lymphoma with dacarbazine in a dog. (Tratamiento del linfoma cutáneo de celulas T con dacarbazina en un perro.) Veterinary Dermatology 1997; 8 : 41–46.] Zusammenfassung— Es wird über eine epitheliotropes kutanes T-Zell-Lymphom bei einem Lhasa Apso berichtet, das mit Dacarbazin behandelt wurde. Die klinische Erkrankung bestand in einer 4 × 4 cm großen ulzerierten Masse über der Symphyse der Mandibula sowie einer bilateralen Lymphadenopathie der submandibulären Lymphknoten. Die Hautbiopsien ergaben die Diagnose epitheliotropes kutanes T-Zell-Lymphom, die immunohistochemische Färbung auf CD3-Antigen fiel positiv aus. Die Gewebsproben wurden einer Chemosensitivitätsprobe unterzogen und Dacarbazin erwies sich zu 60% wirksam. Die Behandlung mit Dacarbazin führte zu einer vollständigen klinischen Remission. Der Hund blieb frei von Krankheitssymptomen seit einem Jahr nach der Behandlung. [Lemarié, S. L., Eddlestone, S. M. Treatment of cutaneous T-cell lymphoma with dacarbazine in a dog. (Die Behandlung eines kutanen T-Zell-Lymphom mit Dacarbazin bei einem Hund.) Veterinary Dermatology 1997; 8 : 41–46.]     

犬皮下注射麻保沙星生物利用度的研究

为了研究麻保沙星在犬皮下给药的生物利用度,将18只犬随机分成2组,按照2mg/kg分别皮下注射或静脉注射麻保沙星后,采血待检,2周后两组交叉给药后,采血。分别在药物注射后5、10、15、30、45min,1、1.5、2,4、6,8、12、24、36、72h时采集血液。血浆通过高效液相色谱法检测药物浓度,用3P97药代动力学软件进行分析。麻保沙星皮下注射的平均药代动力学参数为:t1/2ka=0.19±0.08h;t1/2ke=7.21±1.88h;tmax=0.97±0.29h;Cmax=1.13±0.17μg/mL;AUC=13.13±4.24μg·h/mL;CL=0.17±0.05L/h;V/F=1.63±0.24L/kg。犬皮下注射麻保沙星的绝对生物利用度为66.7%,皮下注射能迅速被吸收且有较高的组织渗透性。     

Pharmacokinetics of hydromorphone hydrochloride in healthy dogs

ObjectiveTo assess the pharmacokinetics of hydromorphone administered intravenously (IV) or subcutaneously (SC) to dogs.Study designRandomized experimental trial.AnimalsSeven healthy male neutered Beagles aged 12.13 ± 1.2 months and weighing 11.72 ± 1.10 kg.MethodsThe study was a randomized Latin square block design. Dogs were randomly assigned to receive hydromorphone hydrochloride 0.1 mg kg⁻¹ or 0.5 mg kg⁻¹ IV (n = 4 dogs) or 0.1 mg kg⁻¹ (n = 6) or 0.5 mg kg⁻¹ (n = 5) SC on separate occasions with a minimum 14-day washout between experiments. Blood was sampled via a vascular access port at serial intervals after drug administration. Serum was analyzed by mass spectrometry. Pharmacokinetic parameters were determined with computer software.ResultsSerum concentrations of hydromorphone decreased quickly after both routes of administration of either dose. The serum half-life, clearance, and volume of distribution after IV hydromorphone at 0.1 mg kg⁻¹ were 0.57 hours (geometric mean), 106.28 mL minute⁻¹ kg⁻¹, and 5.35 L kg⁻¹, and at 0.5 mg kg⁻¹ were 1.00 hour, 60.30 mL minute⁻¹ kg⁻¹, and 5.23 L kg⁻¹, respectively. The serum half-life after SC hydromorphone at 0.1 mg kg⁻¹ and 0.5 mg kg⁻¹ was 0.66 hours and 1.11 hours, respectively.Conclusions and clinical relevanceHydromorphone has a short half-life, suggesting that frequent dosing intervals are needed. Based on pharmacokinetic parameters calculated in this study, 0.1 mg kg⁻¹ IV or SC q 2 hours or a constant rate infusion of hydromorphone at 0.03 mg kg⁻¹ hour⁻¹ are suggested for future studies to assess the analgesic effect of hydromorphone.     

Epitheliotropic cutaneous lymphoma (mycosis fungoides) in a dog

A seven-year-old castrated male Yorkshire terrier dog was presented for a recurrent skin disease. Erythematous skin during the first visit progressed from multiple plaques to patch lesions and exudative erosion in the oral mucosa membrane. Biopsy samples were taken from erythematous skin and were diagnosed with epitheliotropic T cell cutaneous lymphoma by histopathology and immunochemical stain. In serum chemistry, the dog had a hypercalcemia (15.7 mg/dl) and mild increased alkaline phosphatase (417 U/l). Immunohistochemistry was performed to detect parathyroid hormone-related peptide (PTH-rP) in epitheliotropic cutaneous lymphoma tissues but the neoplastic cells were not labeled with anti-PTH-rP antibodies. The patient was treated with prednisolone and isotretinoin. However, the dog died unexpectedly.     

MIB‐1 immunoreactivity correlates with biologic behaviour in canine cutaneous melanoma

The growth fraction of 68 canine cutaneous melanomas was determined by immunostaining with MIB‐1, a monoclonal antibody to a Ki‐67 epitope that recognizes all proliferating cells. Fifty tumours were classified histologically as benign and 18 as malignant. The Ki‐67 proliferative index (percentage of positive cells over 500 neoplastic cells) was low (< 15%) in 55 cases and high ( 15%) in 13 cases. High Ki‐67 proliferative index and histological malignancy were both associated with significantly poorer 2‐year survival (P < 0.0001). However, the predictive value of the Ki‐67 proliferative index (97%) was higher than the predictive value of classical histology (91%). The evaluation of the growth fraction by the Ki‐67 proliferative index is highly predictive of the biological behaviour of canine cutaneous melanoma.     

Effect of autologous platelet-rich plasma application on cutaneous wound healing in dogs

This study was conducted to identify the effectiveness of platelet-rich plasma (PRP) and efficacy of intralesional injection as a method of application to acute cutaneous wounds in dogs. Healthy adult beagles (n = 3) were used in this study. Autologous PRP was separated from anticoagulant treated whole blood in three dogs. Cutaneous wounds were created and then treated by intralesional injection of PRP in the experimental group, while they were treated with saline in the control group on days 0, 2 and 4. The healing process was evaluated by gross examination throughout the experimental period and histologic examination on day 7, 14 and 21. In PRP treated wounds, the mean diameter was smaller and the wound closure rate was higher than in the control. Histological study revealed that PRP treated wounds showed more granulation formation and angiogenesis on day 7, and faster epithelialization, more granulation formation and collagen deposition were observed on day 14 than in control wounds. On day 21, collagen deposition and epithelialization were enhanced in PRP treated groups. Overall, PRP application showed beneficial effects in wound healing, and intralesional injection was useful for application of PRP and could be a good therapeutic option for wound management in dogs.